Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment

Table 1 Summary of Changes in Lipid Profiles with Rheumatoid Arthritis Therapies

Study or Author	RA drug	Change in TC (mg/dL)	Change in LDL-C (mg/dL)	Change in HDL-C (mg/dL)	Notes
Yamanaka et al. [171]	TCZ	↑ 12.9	n/a	n/a	Concurrent DMARD use
Yazici et al. [172]	TCZ	↑ 25.9	↑ 17.8	↑ 3.5	Concurrent DMARD use
Genovese et al. [103]	TCZ	↑ 30.9	↑ 3.8	↑ 19.3	Concurrent DMARD use
Gabay et al. [161]	TCZ	↑30.5	↑20.1	↑5.4	Change from baseline to week 8
Gabay et al. [161]	Adalimumab	↑6.6	↑2.7	↑2.7	Change from baseline to week 8
Tam et al. [173]	Infliximab	↑23.2	↑12.4	↑5.8	Change from baseline to week 14
Kirkham et al. [174]	Golimumab	↑8.0	↑8.0	↑3.0
Morris et al. [175]	Hydroxychloroquine	↓ 7.7	↓ 7.6	↑ 1.0
Navarro-Millán et al. [176]	Methotrexate with Etanercept	↑56.8	↑31.4	↑19.3	After 6 months of treatment
	Triple therapy^a	↑53.0	↑28.7	↑22.3
	Methotrexate	↑57.3	↑30.0	↑20.6
Charles-Schoeman et al. [177]^b		↑ week 24	↑ week 24	↑ week 24	Trend of lipids with treatment
Charles-Schoeman et al. [177]^b		↓week 102	↓week 102	↓week 102	Trend of lipids with treatment
Novikova et al. [178]	Rituximab	↑19.7	↑4.6	↑12.0	After 6 months of treatment

TC total cholesterol, LDL-C low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, TCZ tocilizumab
^aTriple therapy=methotrexate plus sulfasalazine plus hydroxychloroquine, DMARD = disease modifying anti-rheumatic drugs
^bAbsolute numerical changes not available

ISSN: 2520-1026